

## Special Issue

# Head and Neck Cancer: Molecular Mechanisms to Therapeutic Advances

### Message from the Guest Editors

Head and neck cancer (HNC) poses significant global health challenges due to its complex molecular pathogenesis and high recurrence rates. This Special Issue, “Head and Neck Cancer: Molecular Mechanisms to Therapeutic Advances,” integrates cutting-edge research on the biological underpinnings of HNC with innovative treatment strategies. This Special Issue aims to bridge the gap between foundational research and clinical application by highlighting cutting-edge studies on the molecular mechanisms of head and neck cancer development and progression. Topics of interest include novel molecular biomarkers, targeted therapies, immunotherapy, and the role of the tumor microenvironment in cancer progression. We also welcome contributions on multidisciplinary treatment approaches, including precision medicine and personalized treatment strategies. We invite original research and reviews on biomarker discovery, tumor heterogeneity, treatment resistance, and clinical trials. The issue aims to serve as a valuable resource for basic scientists, translational researchers, and clinicians working to improve outcomes for HNC patients worldwide.

### Guest Editors

Dr. Jacopo Zocchi

Dr. Irene H. Nauta

Prof. Dr. Carlos M. Chiesa-Estomba

### Deadline for manuscript submissions

31 March 2026



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/248347](https://mdpi.com/si/248347)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).